In a recently published study, a team of researchers led by Dr. Giovanni Mancardi from the University of Genoa conducted a phase II clinical trial to compare the effectiveness of conventional multiple sclerosis [MS] therapy to intravenous stem cell transplantation. Throughout the four year trial, the team found that, in addition to significantly decreasing disease progression and brain damage compared to MS drug mitoxantrone [MTX], the transplanted stem cells had migrated into the patients’ bone marrow and stimulated the generation of new, non-harmful immune cells, essentially resetting the immune system.
StemSave Blog
Multiple Sclerosis Treatment “Resets” Immune System through Stem Cell Transplantation.
Posted by maxi@stemsave.com on Apr 4, 2015 11:36:00 AM
Topics: multiple sclerosis, stemsaveblog, Brain, clinical trials, clinical trial, bone marrow, immune system, neurological disease,, university of genoa,, autoimmune attack, nerve stem cells,